FCN-159
Phase 2Small molecule
FCN-159 is one of 43 small molecule programs targeting Neurofibromatosis Type 1. It is currently in Phase 2.
2
Indications
4
Total Trials
4
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
41 competitors in Neurofibromatosis Type 1
#DrugCompanyPhaseTrials
1Ritalin
NovartisApproved
Verzenio
Eli LillyApproved
Afinitor
NovartisApproved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Levulan
BBiomed Industries, Inc.
Approved
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Lamictal
GGlaxo Dba Glaxosmithkline
Approved
Koselugo
AstraZenecaPhase 2
Cysteine Hydrochloride
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neurofibromatosis Type 11 trial
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
Active, not recruiting·SShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.·Phase 1/2·NCT04954001·160 enrolled
Pediatric Patients1 trial
Venous malformation1 trial
Phase II1 trial
Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors
Recruiting·—·Phase 2·NCT06553365·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FCN-159. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details